CRF news

An innovative clinical trial aiming to improve the treatment of myeloma – currently an incurable blood cancer – has opened at UCLH.

Receiving a third dose of a Covid-19 vaccine approved in the UK offers a prolonged immune response, a study at UCLH has found.

A world-first treatment for Creutzfeldt-Jakob disease (CJD) has shown “very encouraging” early results following its use in six patients at UCLH.

The Clinical Research Facility at UCLH has been awarded £10 million in funding to deliver cutting edge early phase health research in areas including cancer and dementia.

A third ‘booster’ dose of COVID-19 vaccine successfully raises antibody levels that neutralise the Omicron variant.

Six COVID-19 vaccines are safe and boost immunity for people who have had two doses of AstraZeneca or Pfizer-BioNTech, results from the UK-wide COV-BOOST trial show.

People can safely receive the Covid-19 and influenza vaccine at the same time, according to a new study. The ‘Combining Influenza and Covid-19 Vaccination (ComFluCOV) study’ published as a preprint, found that immune responses to both the influenza and Covid-19 vaccine were preserved when given

A clinical trial of a new drug candidate for Alzheimer’s disease which has been developed at UCL in partnership with the pharmaceutical company Eisai has begun at UCLH with participants now being screened.

The first patient in the world has been dosed at the NIHR UCLH Clinical Research Facility (CRF) in a first-in-human trial of a new drug for the rare disease classical homocystinuria.

A trial of a new version of the AstraZeneca vaccine is to start at UCLH to see if it is effective against the Covid-19 variant first identified in South Africa.

Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to research in which UCLH played a key role.

More than nine in ten patients taking part in research at UCLH would consider doing so again and felt valued for their participation, according to a national survey.

Read the first edition of the NIHR UCLH Clinical Research Facility’s (CRF) early phase cancer trials newsletter.

UCLH is the first site in the UK to recruit to an international vaccine study looking at the safety, tolerability and immune response generated by the Pfizer-BioNTech Covid-19 vaccine in healthy pregnant women.